Severe Late Toxicities Following Concomitant Chemoradiotherapy Compared to Radiotherapy Alone in Cervical Cancer: An Inter-era Analysis

被引:85
作者
Gondi, Vinai [1 ]
Bentzen, Soren M. [1 ]
Sklenar, Kathryn L. [1 ]
Dunn, Emily F. [1 ]
Petereit, Daniel G. [1 ,2 ]
Tannehill, Scott P. [3 ,4 ]
Straub, Margaret [1 ]
Bradley, Kristin A. [1 ]
机构
[1] Univ Wisconsin, Dept Human Oncol, Ctr Comprehens Canc, Madison, WI USA
[2] Rapid City Reg Hosp, John T Vucurevich Canc Care Inst, Rapid City, SD USA
[3] Arizona Canc Specialists, Phoenix, AZ USA
[4] Univ Arizona, Dept Radiat Oncol, Tucson, AZ USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2012年 / 84卷 / 04期
关键词
Cervical cancer; Chemotherapy; Late toxicity; Radiotherapy; Vaginal stricture; RATE INTRACAVITARY BRACHYTHERAPY; RADIATION-THERAPY; MADISON SYSTEM; CARCINOMA; COMPLICATIONS; CHEMOTHERAPY;
D O I
10.1016/j.ijrobp.2012.01.064
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To compare rates of severe late toxicities following concomitant chemoradiotherapy and radiotherapy alone for cervical cancer. Methods and Materials: Patients with cervical cancer were treated at a single institution with radiotherapy alone or concomitant chemoradiotherapy for curative intent. Severe late toxicity was defined as grade >= 3 vaginal, urologic, or gastrointestinal toxicity or any pelvic fracture, using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE), occurring >= 6 months from treatment completion and predating any salvage therapy. Severe late toxicity rates were compared after adjusting for pertinent covariates. Results: At 3 years, probability of vaginal severe late toxicity was 20.2% for radiotherapy alone and 35.1% for concomitant chemoradiotherapy (P=.026). At 3 years, probability of skeletal severe late toxicity was 1.6% for radiotherapy alone and 7.5% for concomitant chemoradiotherapy (P=.010). After adjustment for case mix, concomitant chemoradiotherapy was associated with higher vaginal (hazard ratio [HR] 3.0, 95% confidence interval [CI], 1.7-5.2, P<.001), and skeletal (HR 7.0, 95% CI 1.4-34.1, P=.016) severe late toxicity. Compared to high dilator compliance, moderate (HR 3.6, 95% CI 2.0-6.5, P<.001) and poor (HR 8.5, 95% CI 4.3-16.9, P<.001) dilator compliance was associated with higher vaginal severe late toxicity. Age >50 was associated with higher vaginal (HR 1.8, 95% CI 1.1-3.0, P=.013) and skeletal (HR 5.7, 95% CI 1.2-27.0, P=.028) severe late toxicity. Concomitant chemoradiotherapy was not associated with higher gastrointestinal (P=.886) or urologic (unadjusted, P=.053; adjusted, P=.063) severe late toxicity. Conclusion: Compared to radiotherapy alone, concomitant chemoradiotherapy is associated with higher rates of severe vaginal and skeletal late toxicities. Other predictive factors include dilator compliance for severe vaginal late toxicity and age for severe vaginal and skeletal late toxicities. (C) 2012 Elsevier Inc.
引用
收藏
页码:973 / 982
页数:10
相关论文
共 13 条
[1]  
[Anonymous], 2010, Common terminology criteria for adverse events, v4.03
[2]   Vaginal stenosis in patients treated with radiotherapy for carcinoma of the cervix [J].
Brand, AH ;
Bull, CA ;
Cakir, B .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (01) :288-293
[3]   TIME-COURSE AND INCIDENCE OF LATE COMPLICATIONS IN PATIENTS TREATED WITH RADIATION-THERAPY FOR FIGO STAGE IB CARCINOMA OF THE UTERINE CERVIX [J].
EIFEL, PJ ;
LEVENBACK, C ;
WHARTON, JT ;
OSWALD, MJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (05) :1289-1300
[4]   Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of radiation therapy oncology group trial (RTOG) 90-01 [J].
Eifel, PJ ;
Winter, K ;
Morris, M ;
Levenback, C ;
Grigsby, PW ;
Cooper, J ;
Rotman, M ;
Gershenson, D ;
Mutch, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :872-880
[5]   Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer [J].
Eifel, PJ ;
Jhingran, A ;
Bodurka, DC ;
Levenback, C ;
Thames, H .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3651-3657
[6]  
*INT COMM RAD UN M, 1985, 38 ICRU MEAS
[7]   Vaginal dilator therapy for women receiving pelvic radiotherapy [J].
Miles, Tracie ;
Johnson, Nick .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (09)
[8]   Pelvic insufficiency fracture after pelvic radiotherapy for cervical cancer: Analysis of risk factors [J].
Oh, Dongryul ;
Huh, Seung Jae ;
Nam, Heerim ;
Park, Won ;
Han, Youngyih ;
Lim, Do Hoon ;
Ahn, Yong Chan ;
Lee, Jeong Won ;
Kim, Byoung Gie ;
Bae, Duk Soo ;
Lee, Je Ho .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 70 (04) :1183-1188
[9]   Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix [J].
Pearcey, R ;
Brundage, M ;
Drouin, P ;
Jeffery, J ;
Johnston, D ;
Lukka, H ;
MacLean, G ;
Souhami, L ;
Stuart, G ;
Tu, D .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (04) :966-972
[10]  
Schmeler KM, CANCER, V116, P625